Leerink Partnrs Has Pessimistic View of VIR FY2026 Earnings

Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Equities research analysts at Leerink Partnrs reduced their FY2026 earnings per share (EPS) estimates for shares of Vir Biotechnology in a report issued on Wednesday, November 20th. Leerink Partnrs analyst R. Ruiz now forecasts that the company will post earnings per share of ($4.05) for the year, down from their prior forecast of ($3.55). The consensus estimate for Vir Biotechnology's current full-year earnings is ($3.86) per share. Leerink Partnrs also issued estimates for Vir Biotechnology's FY2027 earnings at ($2.80) EPS.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($0.51). The company had revenue of $2.38 million for the quarter, compared to the consensus estimate of $5.54 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. Vir Biotechnology's revenue was down 9.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.22) earnings per share.

A number of other research firms have also recently commented on VIR. Needham & Company LLC reiterated a "buy" rating and set a $19.00 price objective on shares of Vir Biotechnology in a research report on Wednesday. HC Wainwright reiterated a "buy" rating and issued a $110.00 price objective on shares of Vir Biotechnology in a research note on Wednesday. Finally, Barclays dropped their price objective on shares of Vir Biotechnology from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Monday, November 4th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $36.40.

Vir Biotechnology Trading Up 2.4 %

Shares of NASDAQ:VIR traded up $0.17 during midday trading on Friday, reaching $7.12. 891,724 shares of the company's stock traded hands, compared to its average volume of 1,043,675. Vir Biotechnology has a one year low of $6.56 and a one year high of $13.09. The stock has a 50 day moving average of $7.93 and a 200 day moving average of $8.89.

Institutional Trading of Vir Biotechnology

A number of hedge funds have recently bought and sold shares of VIR. Louisiana State Employees Retirement System boosted its holdings in shares of Vir Biotechnology by 2.8% in the 2nd quarter. Louisiana State Employees Retirement System now owns 43,800 shares of the company's stock valued at $390,000 after buying an additional 1,200 shares in the last quarter. ProShare Advisors LLC lifted its position in Vir Biotechnology by 8.4% during the first quarter. ProShare Advisors LLC now owns 26,392 shares of the company's stock valued at $267,000 after acquiring an additional 2,035 shares during the last quarter. Blue Trust Inc. lifted its position in Vir Biotechnology by 143.5% during the third quarter. Blue Trust Inc. now owns 3,989 shares of the company's stock valued at $30,000 after acquiring an additional 2,351 shares during the last quarter. Public Sector Pension Investment Board boosted its stake in Vir Biotechnology by 1.4% in the third quarter. Public Sector Pension Investment Board now owns 194,208 shares of the company's stock valued at $1,455,000 after acquiring an additional 2,600 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Vir Biotechnology by 15.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,647 shares of the company's stock worth $219,000 after purchasing an additional 3,215 shares during the last quarter. Hedge funds and other institutional investors own 65.32% of the company's stock.

Insider Activity at Vir Biotechnology

In other news, Director Janet Napolitano sold 12,190 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $7.80, for a total transaction of $95,082.00. Following the transaction, the director now owns 11,616 shares of the company's stock, valued at approximately $90,604.80. This represents a 51.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 15,940 shares of company stock worth $127,410 in the last 90 days. 15.60% of the stock is owned by corporate insiders.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).